No Data
No Data
Critical Insights From Calliditas Therapeutics Analyst Ratings: What You Need To Know
In the last three months, 5 analysts have published ratings on Calliditas Therapeutics (NASDAQ:CALT), offering a diverse range of perspectives from bullish to bearish.The table below offers a condense
Calliditas Therapeutics Cut to Neutral From Buy by Citigroup
Calliditas Therapeutics Cut to Neutral From Buy by Citigroup
Calliditas Therapeutics Price Target Announced at $39.00/Share by Citigroup
Calliditas Therapeutics Price Target Announced at $39.00/Share by Citigroup
Citi Downgrades Calliditas to Neutral, Cites Takeover Offer
Citigroup Downgrades Calliditas Therapeutics to Neutral From Buy, Price Target at $39
Calliditas Therapeutics' (CALT) US stock has an average investment rating of hold among analysts polled by Capital IQ, with price targets ranging from $39 to $40. Price: 39.17, Change: +0.19, Percent
Calliditas Partner Secures European Panel Backing for Rare Kidney Disease Treatment
Calliditas Therapeutics' (CALTX.ST) commercial partner received a positive opinion recommending full European Union marketing authorization for Kinpeygo for the treatment of primary immunoglobulin A n